Literature DB >> 2157071

A transformation-competent recombinant between v-src and Rous-associated virus RAV-1.

J Svoboda1, J C Kandala, J Geryk, J Pichrtová, R V Guntaka.   

Abstract

The LTR, v-src, LTR provirus, which arose by the reverse transcription and integration of src mRNA in the H-19 hamster tumor, has been successfully rescued by fusion with chicken fibroblasts infected with Rous-associated virus RAV-1. One rescued virus, E6, acquired 1 kilobase of the 5' end of the gag gene structure. Recombination took place in the region of 15-nucleotide homology exactly between v-src exon (position 7054) and gag (position 1417). This recombination resulted in the alteration of src splice acceptor site sequences, but this site is maintained as a functional splice acceptor site. The nucleotide structure of the long terminal repeat of recombinant E6 virus suggests that it arose by the intermolecular jump of reverse transcription from RAV-1 to src mRNA and then the switch of templates between already depicted regions of homology. The second jump of reverse transcription was apparently an intramolecular event. The acquisition of 1 kilobase of the 5' gag by E6 resulted in maintaining the balance of unspliced and spliced E6 RNAs and assured the replication advantage of rescued E6 virus over rescued F6 virus, the genome of which corresponds to that present in ancestral H-19 cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157071      PMCID: PMC249334          DOI: 10.1128/JVI.64.4.1873-1877.1990

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

Review 1.  Structure, replication, and recombination of retrovirus genomes: some unifying hypotheses.

Authors:  J M Coffin
Journal:  J Gen Virol       Date:  1979-01       Impact factor: 3.891

2.  Structural analysis of proviruses in additional hamster tumour cell lines transformed by provirus II rescued from XC cells and definition of a new cell line harbouring amplified proviruses.

Authors:  J Pichrtová; J Geryk; J Svoboda
Journal:  Folia Biol (Praha)       Date:  1989       Impact factor: 0.906

3.  Complete nucleotide sequence of LTR, v-src, LTR provirus H-19.

Authors:  J Bodor; E Poliak; J Pichrtová; J Geryk; J Svoboda
Journal:  Nucleic Acids Res       Date:  1989-11-11       Impact factor: 16.971

4.  Synthesis of murine leukemia virus plus strong stop DNA initiates at a unique site.

Authors:  S W Mitra; M Chow; J Champoux; D Baltimore
Journal:  J Biol Chem       Date:  1982-06-10       Impact factor: 5.157

5.  A new replication-defective variant of the Bryan high-titer strain Rous sarcoma virus.

Authors:  H M Murphy
Journal:  Virology       Date:  1977-04       Impact factor: 3.616

6.  Nucleotide sequence of Rous sarcoma virus.

Authors:  D E Schwartz; R Tizard; W Gilbert
Journal:  Cell       Date:  1983-03       Impact factor: 41.582

7.  Structure of a replication intermediate in the synthesis of Rous sarcoma virus DNA in vivo.

Authors:  R Swanstrom; J M Bishop; H E Varmus
Journal:  J Virol       Date:  1982-04       Impact factor: 5.103

8.  A catalogue of splice junction sequences.

Authors:  S M Mount
Journal:  Nucleic Acids Res       Date:  1982-01-22       Impact factor: 16.971

9.  An avian tumor virus promoter directs expression of plasmid genes in Escherichia coli.

Authors:  S A Mitsialis; J F Young; P Palese; R V Guntaka
Journal:  Gene       Date:  1981-12       Impact factor: 3.688

10.  Cloning of avian tumor virus DNA fragments in plasmid pBR322: evidence for efficient transcription in E. coli from a virus-coded promoter.

Authors:  R V Guntaka; S A Mitsialis
Journal:  Gene       Date:  1980-12       Impact factor: 3.688

View more
  2 in total

1.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1990-08-25       Impact factor: 16.971

Review 2.  The Importance of Being Non-Defective: A Mini Review Dedicated to the Memory of Jan Svoboda.

Authors:  Peter K Vogt
Journal:  Viruses       Date:  2019-01-18       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.